ENDVOTCElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
ENDONOVO THERAPEUTICS, INC.
Financials through Q3 FY2023, quarter ended Sep 30, 2023Last filing: 10-Q/A on Dec 29, 2023
$0.00+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $135.08K
- P/E (TTM)
- –
- Dividend yield
- –
ENDONOVO THERAPEUTICS, INC. revenue by segment
By business segment
By product or service
| Revenue | Q3 23 | Q2 23 | Q1 23 | Q4 22 | Q3 22 | Q2 22 | Q1 22 | Q4 21 | Q3 21 | Q2 21 | Q1 21 | Q4 20 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Direct Sales Medical Care Providers Gross [Member] | $1.52K | $0 | $6.22K | $7.84K | $10.96K | $650 | $2.28K | $316 | $7.79K | $30.28K | $34.72K | $11.50K | 100.0% | -86.1% |
| Royalty/Licensing, Net [Member] | $0 | $45.20K | $81.32K | – | – | – | – | – | – | – | – | – | 0.0% | – |
By region
From the segment and revenue-disaggregation notes of Endonovo Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.